Filing identity and reporting period
Important identity discrepancy: The supplied filing is Cyclacel Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2021—not a filing by Bio Green Med Solution, Inc. The summary below covers Cyclacel.
Cyclacel is a clinical-stage biopharmaceutical company developing cancer medicines. Its programs include fadraciclib, CYC140, and sapacitabine combinations. It reported no revenue for the quarter.
Financial results and liquidity
Amounts below are in U.S. dollars; financial statement figures are in millions unless otherwise noted.
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.566 | $1.106; up 132% |
| General and administrative expense | $1.739 | $1.318; up 32% |
| Total operating expense | $4.305 | $2.424 |
| Operating loss | $(4.305) | $(2.424) |
| Other income, net | $0.140 | $0.914 |
| Income tax benefit | $0.687 | $0.290 |
| Net loss | $(3.478) | $(1.220) |
| Net loss applicable to common shareholders | $(3.528) | $(1.270) |
| Basic and diluted loss per share | $(0.50) | $(1.48) |
| Net cash used in operating activities | $(3.566) | $(2.807) |
Cash and cash equivalents were $47.777 million at March 31, 2021, up from $33.406 million at December 31, 2020. Working capital was $47.691 million. Total liabilities were $3.768 million, including $0.996 million of lease liabilities; the filing does not report conventional debt outstanding. The accumulated deficit was $369.550 million. The company reported no meaningful revenue base from which to assess operating margins.
Financing cash inflows were $17.997 million: approximately $13.5 million net proceeds from a March underwritten stock offering and approximately $4.5 million from warrant exercises, partly offset by preferred dividends. Capital expenditures were $0.078 million. Cash increased by $14.371 million during the quarter.
Material changes versus the prior comparable period
- R&D expense rose $1.460 million, primarily as fadraciclib clinical evaluation progressed and CYC140 preclinical work and clinical-trial supply manufacturing advanced.
- G&A expense increased $0.421 million, reflecting higher legal, professional, and recruitment costs associated with expanding the clinical team.
- Net loss widened by $2.258 million. Other income fell $0.774 million, largely because royalty-related income under an asset purchase agreement was $0.126 million versus $0.817 million in Q1 2020.
- Loss per share improved to $0.50 from $1.48 despite the larger net loss, in part because weighted-average common shares increased to 7.099 million from 0.860 million following equity issuances. The company completed a one-for-twenty reverse stock split in April 2020; share and per-share data are retrospectively adjusted.
- Common shares outstanding increased from 6.247 million at year-end 2020 to 9.234 million at March 31, 2021. The March financing issued 2.078 million shares including the overallotment; 909,000 warrants were also exercised during the quarter.
Outlook, risks, and unusual items
- Management estimated that March 31 cash would fund operating expenses and capital expenditures through early 2023. Additional capital will be needed beyond that point, and the company said it does not have sufficient funds to complete development and commercialization of any candidate.
- Management expected 2021 R&D expense to increase from 2020 as clinical programs advance, while G&A expense was expected to decrease slightly. It expected higher U.K. R&D tax credits due to higher eligible expenses. No revenue guidance or specific clinical milestones are provided in the supplied text.
- The company has no active collaboration, licensing, or clinical supply agreements and expects no revenue for the foreseeable future. Future funding may require equity, debt, or strategic collaborations; funding may not be available on acceptable terms. Failure to raise capital could delay, reduce, or eliminate trials or programs, or require earlier partnering on less favorable economics.
- COVID-19’s impact was uncertain and could affect clinical study timing and access to capital. The filing says management did not identify conditions raising substantial doubt about the company’s ability to continue as a going concern for at least one year from issuance.
- Other income includes royalties under a 2005 asset purchase agreement; the company cannot estimate their level or timing because they depend on sales by ThermoFisher Scientific. Q1 2021 also included a $0.126 million royalty receivable presented as other income.
- As a subsequent event, Cyclacel assigned its Dundee, Scotland lease on May 4, 2021, paying an approximately $0.400 million reverse premium and ending further obligations on that facility. A declared $0.15-per-share quarterly dividend on 6% preferred stock was paid May 1, 2021.
- The company reported no legal proceedings, no material changes to its previously disclosed risk factors, and effective disclosure controls as of March 31, 2021.
Most important facts for investors to verify
- Confirm the issuer: the provided 10-Q is Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc.
- Assess whether the stated cash runway through early 2023 remains adequate against trial spending, the subsequent $0.400 million lease payment, and other obligations.
- Review the clinical progress, costs, and timing of the fadraciclib, CYC140, and sapacitabine programs, along with potential COVID-19 effects.
- Evaluate dilution and potential share supply from recent offerings, outstanding warrants and preferred stock, and stock options.
- Check the sustainability and timing of royalty income and U.K. R&D tax-credit receipts, neither of which is assured at the reported level.